Vertex Pharma (VRTX) Misses Q3 EPS by 9c
Tweet
Share
E-mailGet Alerts VRTX Hot Sheet
Price: $468.42 +0.35%
EPS Growth %: +4.4%
Financial Fact:
Total costs and expenses: 432.51M
Today's EPS Names:
CBRS, MAYS, CRMT, More
EPS Growth %: +4.4%
Financial Fact:
Total costs and expenses: 432.51M
Today's EPS Names:
CBRS, MAYS, CRMT, More
Join SI Premium – FREE
Vertex Pharma (NASDAQ: VRTX) reported Q3 EPS of ($0.39), $0.09 worse than the analyst estimate of ($0.30). Revenue for the quarter came in at $309.8 million versus the consensus estimate of $245.84 million.
For earnings history and earnings-related data on Vertex Pharma (VRTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Nike names former Pfizer CFO David Denton as new finance chief
- BofA lists top 5 themes driving next $1tn in incremental semi sales
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
